Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Behenic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 7/20 | 0.94 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.94 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.94 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.94 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.94 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.94 |
| ▸ | PPARD | Q03181 | 7/20 | 0.94 |
| ▸ | PPARA | Q07869 | 7/20 | 0.94 |
| ▸ | TSHR | P16473 | 4/20 | 0.94 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.94 |
| ▸ | FABP4 | P15090 | 3/20 | 0.94 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.94 |
| ▸ | TLR2 | O60603 | 2/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.94 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.94 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.94 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.94 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.94 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.94 |
| ▸ | MEN1 | O00255 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palmitic Acid SCHEMBL7556500 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Lignoceric Acid SCHEMBL3674713 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonanoate SCHEMBL4152676 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Pentadecanoic Acid SCHEMBL6712161 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Heptanoate SCHEMBL19994751 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Nonanoate SCHEMBL20572899 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Dodecanoate SCHEMBL23581128 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Tridecanoate SCHEMBL1994545 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Palmitic Acid SCHEMBL539137 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 | |
| Heneicosanoic Acid SCHEMBL7907716 | 1.00 | GPR84 (0.94) | GPR84PPARGPPARDPPARAHDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122012182-A | Method for synthesizing branched fatty acid ester of hydroxy fatty acid by taking natural oil containing hydroxy fatty acid as raw material | 江南大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260022520-A1 | METHOD FOR ACYLATING A HYDROXYLATED SOLID MATERIAL | CELLULOTECH INC (CA) | 2026-01-22 | — | — | US | claimed |
| EP-4466401-A1 | METHOD FOR ACYLATING A HYDROXYLATED SOLID MATERIAL | Cellulotech Inc. (CA) | 2024-11-27 | — | — | EP | claimed |
| WO-2023233202-A1 | METHOD FOR ACYLATING A HYDROXYLATED SOLID MATERIAL | CELLULOTECH INC (CA) | 2023-12-07 | — | — | WO | claimed |
| CN-111485450-A | Preparation method of high-melting-point AKD sizing agent | 济宁明升新材料有限公司 | 2020-08-04 | — | — | CN | claimed |
| CN-105724601-B | Oil and fat composition and use thereof | 丰益(上海)生物技术研发中心有限公司 | 2020-03-06 | — | — | CN | claimed |
| US-6342268-B1 | TREATMENT OF SOLIDS WITH PROTOGENIC HYDROPHILIC FUNCTION. GRAFTING WITH RX AND FORMING SOLID, APPLYING MICRODISPERSION | BT3 TECHNOLOGIES (FR) | 2002-01-29 | — | — | US | claimed |
| EP-1007202-B1 | METHOD FOR TREATING A SOLID MATERIAL TO MAKE IT HYDROPHOBIC, MATERIAL OBTAINED AND USES | SAMAIN DANIEL (FR) | 2001-07-04 | — | — | EP | claimed |
| US-4272502-A | Process for preparing gaseous hydrogen chloride from dilute aqueous hydrochloric acid | CHEMISCHE WERKE HULS AKTIENGESELLSCHAFT (DE) | 1981-06-09 | — | — | US | claimed |
| JP-1006288-A | — | — | None | — | — | JP | disclosed |
| US-12571164-B2 | Method and device for acylating a moving hydroxylated material | CELLULOTECH INC (CA) | 2026-03-10 | — | — | US | disclosed |
| US-20260022520-A1 | METHOD FOR ACYLATING A HYDROXYLATED SOLID MATERIAL | CELLULOTECH INC (CA) | 2026-01-22 | — | — | US | disclosed |
| US-20250075434-A1 | METHOD AND DEVICE FOR ACYLATING A MOVING HYDROXYLATED MATERIAL | CELLULOTECH INC (CA) | 2025-03-06 | — | — | US | disclosed |
| CN-116375735-B | Antiviral prodrugs and nano-formulations thereof | 内布拉斯加大学董事会 | 2024-12-10 | — | — | CN | disclosed |
| US-6191182-B1 | SUBJECTING P-HALOPHENYL ALKYL KETONE TO AMINOLYSIS WITH CYCLIC SECONDARY AMINE TO FORM CYCLIC AMINE-SUBSTITUTED PHENYL ALKYL KETONE; HALOGINATION AND REACTING WITH AMINE COMPOUND; STEVENS REARRANGEMENT UNDER BASIC CONDITION | CIBA SPECIALTY CHEMCIALS CORPORATION | 2001-02-20 | — | — | US | disclosed |
| US-5977357-A | Phenyl alkyl ketone substituted by cyclic amine and a process for the preparation thereof | CIBA SPECIALTY CHEMICAL CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| US-5795985-A | Phenyl alkyl ketone substituted by cyclic amine and a process for the preparation thereof | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| US-4406889-A | IMMUNOLOGY, PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1983-09-27 | — | — | US | disclosed |
| US-4272502-A | Process for preparing gaseous hydrogen chloride from dilute aqueous hydrochloric acid | CHEMISCHE WERKE HULS AKTIENGESELLSCHAFT (DE) | 1981-06-09 | — | — | US | disclosed |
| US-4153694-A | NEUROLEPTIC AGENTS | KEFALAS A/S (DK) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12571164-B2 | Method and device for acylating a moving hydroxylated material | HAO2, LIPA, DGAT2 | PPARG 138/4885HDAC11 2151/4885ESR1 2119/4885 |
| US-20260022520-A1 | METHOD FOR ACYLATING A HYDROXYLATED SOLID MATERIAL | ELOVL3, ELOVL1, ACSL1 | PPARG 448/4885HDAC11 728/4885ESR1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.